CDKN1A and breast cancer: In liver cancer (41), esophageal cancer (42), lung cancer (43), breast cancer (44), cervical cancer (45) and acute leukemia (46), it has been reported that upstream molecules can be modified by m6A and play an important role through the p21 pathway.